CAMBRIDGE, Mass., Sept. 3, 2025 /PRNewswire/ — Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drugs that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced multiple…